共 50 条
- [23] Known brain metastases: a valid exclusion criterion in non-small cell lung cancer (NSCLC) clinical trials? An audit of the eligibility criteria in NSCLC trials, and an evaluation of treatment delivery, toxicity and survival experienced by patients with brain metastases in NCIC clinical trial group (CTG) trials JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S288 - S289
- [29] A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy.: A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 622S - 622S